---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-051964"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-08-03T21:15:26+00:00"
generated_at: "2026-08-03T21:16:08.544326+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Repligen CEO sends video to BioLife employees; merger expected to close in Q4 2026

## Summary
- Repligen CEO Olivier Loeillot recorded video message for BioLife employees on August 3, 2026.
- Merger still requires regulatory and shareholder approvals; expected close in Q4 2026.
- Repligen describes itself as a bioprocessing tools company with ~2,000 employees globally.
- BioLife's CryoStor platform supports majority of US cell-based therapy trials.
- Until close, BioLife and Repligen will operate as separate independent companies.

## SEC filing metadata
- accession: 0001628280-26-051964
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-08-03T21:15:26+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/0001628280-26-051964-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026051964/blfs-20260803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-051964
- JSON: https://secwatch.observer/filing/0001628280-26-051964.json
- Plain text: https://secwatch.observer/filing/0001628280-26-051964.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.